Sana Biotechnology Inc (SANA) Stock Price, Quote & News

Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modifi...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 701 7914

Website: www.sana.com

Address:

188 East Blaine Street, Suite 400, Seattle, United States

CapitalMonk Sep. 3 at 5:36 PM

$SANA Price: $3.89 (+0.13%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±3.16% RSI: 55.1 | Momentum: Moderate Volume: -68.8% vs avg Volatility: 4.92% Support: $3.37 | Resistance: $4.22 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

CapitalMonk Sep. 2 at 6:47 PM

$SANA Price: $3.90 (+1.96%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±4.10% RSI: 52.9 | Momentum: Moderate Volume: -43.5% vs avg Volatility: 4.96% Support: $3.35 | Resistance: $4.22 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

BriOnH Sep. 2 at 4:38 PM

$SANA I am not feeling very bullish with no Mayo news but the chart is feeling very bullish. Such a pretty setup. Have a Cup and Handle (again) potentially leading to a breakout. Need to push above critical resistance (red line) 4.09, and hopefully just blast through. <=3.52 is the stop. No trades open for me right now in Sana, but considering it. Obviously have my investment position ive been acquiring over the past however many years its been now, that doesn't get any shares sold until I get sc451, or God forbid some unforeseen craziness in trials.

2 · Reply

mirko_papuga Sep. 2 at 3:16 PM

$SANA Bought 400 shares at $3.82 this morning. Hanging in until the Investor Calls next week. Good luck to everyone!

1 · Reply

LoveRetailFroth Sep. 2 at 1:33 PM

$AMLX Good Morning my Bio 💎s ☕️$SMMT $RXRX $SANA

0 · Reply

JerryMalone32 Sep. 1 at 8:22 PM

$SANA conferences!

1 · Reply

CapitalMonk Sep. 1 at 7:38 PM

$SANA Price: $3.83 (-1.03%) Trend: Bearish Market Bias (7D): Bearish Bias 📉 Expected Range: ±5.29% RSI: 50.9 | Momentum: Moderate Volume: -49.7% vs avg Volatility: 5.14% Support: $3.24 | Resistance: $4.22 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

BriOnH Sep. 1 at 4:47 PM

$SANA IF Mayo elected they have 10-20 days to close. Sec "3.2 Second Closing" in https://www.sec.gov/Archives/edgar/data/1770121/000119312526152868/sana-ex10_1.htm But also fear this could've been fair warning from the Aug 10q:"As of the filing of this Quarterly Report, Mayo Clinic has not elected to purchase the Additional Shares." While it isn't the end of the world, or sc451, if Mayo didn't agree to the 2nd tranche, it is in my _opinion_ a very red flag, and if I had to guess it's something around ph 1/2 scheduling. Time will tell what's happening or what happened with Mayo and the second tranche. Anyone else feeling a little disappointed here too as of right now?

2 · Reply

JerryMalone32 Sep. 1 at 12:37 AM

In past years, $SANA has done investor conferences with brokerage houses the week after labor day. Maybe they will announce something this week for that?

1 · Reply

CapitalMonk Aug. 31 at 10:19 PM

$SANA Price: $3.87 (-5.38%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±0.57% RSI: 55.4 | Momentum: Moderate Volume: -12.4% vs avg Volatility: 5.12% Support: $3.05 | Resistance: $4.22 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

Sana Biotechnology to Present at September 2026 Investor Conferences

2026-08-16T13:45:39.000Z - 18 days ago

Sana Biotechnology price target lowered to $6 from $7 at BofA

2026-08-10T20:46:01.000Z - 24 days ago

Sana Biotechnology reports Q2 EPS (13c), consensus (12c)

Aug 10, 2026, 4:00 PM EDT - 24 days ago

Sana Biotechnology Earnings release: Q2 2026

Aug 10, 2026, 4:00 PM EDT - 24 days ago

Sana Biotechnology Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 24 days ago

Sana Biotechnology Slides: Corporate presentation

Jul 29, 2026, 10:09 AM EDT - 5 weeks ago

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

2026-07-13T13:30:18.000Z - 7 weeks ago

Sana Biotechnology announces publication of long-term diabetes data

Jul 13, 2026, 8:00 AM EDT - 7 weeks ago

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Jul 1, 2026, 9:00 AM EDT - 2 months ago

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

Jun 9, 2026, 4:00 PM EDT - 2 months ago

Sana Biotechnology Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 9:20 AM EDT - 3 months ago

Sana Biotechnology Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 4:05 PM EDT - 3 months ago

Sana Biotechnology to Present at June 2026 Investor Conferences

May 15, 2026, 9:00 AM EDT - 3 months ago

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

2026-05-12T22:28:22.000Z - 3 months ago

Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy

May 12, 2026, 5:20 PM EDT - 3 months ago

Sana Biotechnology Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 4:05 PM EDT - 3 months ago

Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

2026-05-11T20:42:28.000Z - 3 months ago

Sana Biotechnology reports Q1 non-GAAP EPS (14c), consensus (15c)

May 11, 2026, 4:05 PM EDT - 3 months ago

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 4:00 PM EDT - 3 months ago

Sana Biotechnology Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Sana Biotechnology Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Sana Biotechnology Slides: Corporate presentation

2026-05-11T17:02:47.000Z - 3 months ago

Sana Biotechnology initiated with a Buy at Rodman & Renshaw

May 5, 2026, 4:05 PM EDT - 4 months ago

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

Apr 27, 2026, 4:30 PM EDT - 4 months ago

Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Sana Biotechnology Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Sana Biotechnology Proxy statement: Proxy filing

2026-04-14T13:23:10.000Z - 4 months ago

Sana Biotechnology price target raised to $7 from $6 at Wedbush

2026-04-13T20:18:08.000Z - 4 months ago

Sana Biotechnology announces SC451 strategic collaboration with Mayo Clinic

Apr 13, 2026, 7:00 AM EDT - 4 months ago

Sana Biotechnology Slides: Corporate presentation

2026-03-13T13:10:51.000Z - 5 months ago

Sana announces follow-up results from first-in-human study transplanting UP421

Mar 11, 2026, 1:40 PM EDT - 5 months ago

Sana Biotechnology Transcript: The Citizens Life Sciences Conference 2026

2026-03-03T22:25:38.000Z - 6 months ago

Sana Biotechnology files automatic mixed securities shelf

2026-03-03T21:25:24.000Z - 6 months ago

Sana Biotechnology reports Q4 EPS (16c), consensus (13c)

Mar 3, 2026, 4:05 PM EST - 6 months ago

Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Mar 3, 2026, 3:00 PM EST - 6 months ago

Sana Biotechnology Annual report: Q4 2025

Mar 3, 2026, 3:00 PM EST - 6 months ago

Sana Biotechnology Earnings release: Q4 2025

Mar 2, 2026, 1:10 PM EST - 6 months ago

Sana Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 4:05 PM EST - 6 months ago

Sana Biotechnology to Present at March 2026 Investor Conferences

2026-02-17T14:16:15.000Z - 6 months ago

Sana Biotechnology appoints Piper as EVP, CFO

Jan 14, 2026, 12:45 PM EST - 7 months ago

Sana Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 7 months ago

Sana Biotechnology Slides: Corporate presentation

Jan 7, 2026, 4:26 PM EST - 7 months ago

Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-06T15:25:24.000Z - 8 months ago

Sana Biotechnology price target raised to $7 from $6 at BofA

2025-12-08T14:05:59.000Z - 8 months ago

Sana Biotechnology announces publication of in vivo gene editing

Dec 8, 2025, 9:00 AM EST - 8 months ago

Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Dec 3, 2025, 2:35 PM EST - 9 months ago

Sana Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 2:30 PM EST - 9 months ago

Sana Biotechnology Transcript: Citi Annual Global Healthcare Conference 2025

Nov 24, 2025, 4:05 PM EST - 9 months ago

Sana Biotechnology to Present at December 2025 Investor Conferences

Nov 12, 2025, 1:30 PM EST - 9 months ago

Sana Biotechnology Transcript: TD Cowen Immunology and Inflammation Summit

2025-11-06T23:25:54.000Z - 10 months ago

Sana Biotechnology reports Q3 EPS (16c), consensus (19c)

Nov 6, 2025, 7:00 AM EST - 10 months ago

Sana Biotechnology Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Sana Biotechnology Quarterly report: Q3 2025

Nov 5, 2025, 6:00 PM EST - 10 months ago

Sana Biotechnology Slides: Investor Presentation

2025-10-30T10:25:41.000Z - 10 months ago

Sana Biotechnology price target raised to $8 from $5 at Citizens JMP

2025-10-15T17:45:20.000Z - 10 months ago

Sana Biotechnology strength attributed to EMJ Capital long call

2025-09-24T11:45:09.000Z - 11 months ago

Wedbush bullish on Sana Biotechnology, initiates with an Outperform

Sep 9, 2025, 9:30 AM EDT - 11 months ago

Sana Biotechnology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:30 AM EDT - 12 months ago

Sana Biotechnology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 8:00 AM EDT - 12 months ago

Sana Biotechnology Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 3:15 PM EDT - 1 year ago

Sana Biotechnology Transcript: Citi's Biopharma Back to School Conference

Aug 28, 2025, 8:00 AM EDT - 1 year ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX IQV MRNA

Aug 26, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology to Present at September 2025 Investor Conferences

Aug 20, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 11, 2025, 12:30 PM EDT - 1 year ago

Sana Biotechnology Quarterly report: Q2 2025

Aug 11, 2025, 12:30 PM EDT - 1 year ago

Sana Biotechnology Earnings release: Q2 2025

Aug 6, 2025, 11:24 PM EDT - 1 year ago

Sana Biotechnology Announces Pricing of Public Offering

Aug 6, 2025, 4:38 PM EDT - 1 year ago

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

MCRB

Aug 4, 2025, 11:35 AM EDT - 1 year ago

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Jun 23, 2025, 10:05 AM EDT - 1 year ago

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Jun 10, 2025, 8:40 AM EDT - 1 year ago

Sana Biotechnology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

Jun 4, 2025, 2:35 PM EDT - 1 year ago

Sana Biotechnology Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Sana Biotechnology Slides: Corporate Presentation

May 28, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology to Present at June 2025 Investor Conferences

May 13, 2025, 12:20 PM EDT - 1 year ago

Sana Biotechnology Transcript: BofA Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 1 year ago

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

CapitalMonk Sep. 3 at 5:36 PM

0 · Reply

CapitalMonk Sep. 2 at 6:47 PM

0 · Reply

BriOnH Sep. 2 at 4:38 PM

2 · Reply

mirko_papuga Sep. 2 at 3:16 PM

$SANA Bought 400 shares at $3.82 this morning. Hanging in until the Investor Calls next week. Good luck to everyone!

1 · Reply

LoveRetailFroth Sep. 2 at 1:33 PM

$AMLX Good Morning my Bio 💎s ☕️$SMMT $RXRX $SANA

0 · Reply

JerryMalone32 Sep. 1 at 8:22 PM

$SANA conferences!

1 · Reply

CapitalMonk Sep. 1 at 7:38 PM

0 · Reply

BriOnH Sep. 1 at 4:47 PM

2 · Reply

JerryMalone32 Sep. 1 at 12:37 AM

In past years, $SANA has done investor conferences with brokerage houses the week after labor day. Maybe they will announce something this week for that?

1 · Reply

CapitalMonk Aug. 31 at 10:19 PM

0 · Reply

JerryMalone32 Aug. 31 at 4:25 PM

Companies have 4 business days to file a form 8-K from the date of the material event so if Mayo opts in I would think an SEC filing by $SANA would be from today thru Friday.

1 · Reply

LoveRetailFroth Aug. 31 at 3:38 PM

$RXRX Good Morning ☕️ Keep adding I guess. $ARBE $VIVO $SANA

0 · Reply

OnlyInvestor Aug. 31 at 2:01 PM

Interest rate speculation is taking a fat 💩 on my small caps this month, even the ones with decent debt structure 😭😭😭 $IWM $SPIR $SANA $AMPG

0 · Reply

Boxcar66 Aug. 31 at 11:46 AM

$SANA In

0 · Reply

JerryMalone32 Aug. 31 at 6:15 AM

$SANA look at this back-and-forth between Bob Nelsen of ARCH Ventures, a co-founder of Sana and Adam Feuerstein, a snarky (but smart) biotech journalist. It is sorta intense. LFG.

1 · Reply

JerryMalone32 Aug. 30 at 8:44 PM

$SANA food for thought. If mayo can do 50,000 procedures and charge just 10,000 for each that’s 500 million PER YEAR. IF Mayo buys another 7.5 million shares and Sana stock goes to $100, that’s 750 million. Just illustrating that really really big money can be made through being the partner of Sana on the clinic side. Yes, the investment in Sana stock is nothing to sneeze at. But the bigger return is in the procedures

0 · Reply

JerryMalone32 Aug. 29 at 9:53 PM

From a poster on Twitter re: $SANA

1 · Reply

mirko_papuga Aug. 28 at 8:33 PM

$SANA Picked up another 315 shares today on the dip. Share price will probably go down once Mayo exercises/does dilution, but either way I'm in for 315 more.

0 · Reply

Inflames_swe Aug. 28 at 7:28 PM

$SANA is it possible for us to see the mayobuy if it happens today?

1 · Reply

mirko_papuga Aug. 28 at 4:41 AM

$SANA Ran into these two articles as part of the EU's CORDIS Horizon 2020 Project.. exciting for anyone with T1D or knows of anyone with T1D. Project Information: VANGUARD New Generation Cell Therapy: Bioartificial pancreas offers a potential cure for type 1 diabetes https://cordis.europa.eu/article/id/464698-bioartificial-pancreas-offers-a-potential-cure-for-type-1-diabetes Total cost: € 6 844 625,00 Coordinated by: UNIVERSITE DE GENEVE, Switzerland Project Information: ISLET Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe https://cordis.europa.eu/article/id/466194-transforming-diabetes-care-through-stem-cell-based-therapies Total cost: € 7 999 998,75 Coordinated by HELMHOLTZ ZENTRUM MUENCHEN..., Germany At the time of posting, I have not looked into the details of these project details, how far along they are or if SANA may be involved in any way. Also, not sure if some of these projects are related to the upcoming presentation SANA has for 20 minutes on October 2, 2026 at the symposium of the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 taking place from September 28 - October 2, 2026 in Milan, Italy.

3 · Reply

BiotechButterflies Aug. 27 at 10:09 PM

$SANA ... up and down.. But once ready for clinic... BOOM!... such neat solution to T1D... i alreadt accumulated... now wait for the news

1 · Reply

LoveRetailFroth Aug. 27 at 2:41 PM

$SANA Hold your HIP shorties 😂🤣 SQUEEZE ! $10 plus 🚀

0 · Reply

Market Cap	1.16B
Revenue (ttm)	0.00
Net Income (ttm)	-244.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,638,800
Avg Vol	2,778,788
Day's Range	N/A - N/A
Shares Out	299.36M
Stochastic %K	42%
Beta	2.12
Analysts	Strong Sell
Price Target	$9.38